GDP与CHOP对非特异性外周T细胞淋巴瘤的临床价值

The Clinical Value of GDP and CHOP in Peripheral T-Cell Lymphoma Not Otherwise Specified

摘要: 目的：探讨非特异性外周T细胞淋巴瘤(PTCL-NOS)合理的化疗方案。方法：收集我院有明确病理诊断的非特异性外周T细胞淋巴瘤患者，分为：研究组(接受GDP方案)和对照组(接受CHOP方案)。对比1) 两组治疗后临床疗效。2) 两组中位无进展生存期(PFS)和总生存期(OS)。3) 两组不良反应。结果：两组治疗后临床疗效比较有差异(P < 0.05)；两组无进展生存期和总生存期比较有差异(P < 0.05)；两组不良反应(恶心、呕吐、血液学毒性、感染)比较有差异(P < 0.05)；两组心脏毒性比较无差异(P > 0.05)。结论：与CHOP方案治疗非特异性外周T细胞淋巴瘤相比，GDP方案临床疗效更优，患者预后改善情况更好，安全性好。

Abstract: Objective: To investigate the reasonable chemotherapy regimen for peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Methods: We collected nonspecific peripheral T-cell lymphoma patients with definite pathological diagnosis in our hospital. They were divided into two groups: Study Group (receiving GDP regimen) and control group (receiving CHOP regimen). Comparison: 1) The clinical efficacy of the two groups after treatment. 2) Progression free survival and overall survival in the two groups. 3) Adverse reactions of the two groups. Results: There are differences in clinical efficacy between the two groups after treatment (P < 0.05); differences between progression free survival and overall survival (P < 0.05); difference between the two groups of adverse reactions (nausea, vomiting, infection, hematological toxicity) (P < 0.05); there is no difference between the two groups of cardiac toxicity (P > 0.05). Conclusion: Compared with CHOP regimen in the treatment of peripheral T-cell lymphoma not otherwise specified, GDP regimen has better clinical efficacy, better prognosis, and better safety.